|
|
|
| ALPPS in the treatment of liver cancer with insufficient future liver remnant |
| Jun-Guo Liu a , b , c , d , # , Jun Wang a , b , c , d , # , Wei Sun a , b , c , d , # , Jin-Juan Zhang a , b , c , d , Yi-Jun Wang a , b , c , d , ∗, Gui-Ming Shu a , b , c , d , Cheng Lou a , b , c , d , Zhi Du a , b , c , d |
a Department of Surgery, Third Central Hospital of Tianjin (Third Central Clinical College of Tianjin Medical University), Tianjin 300170, China
b Tianjin Institute of Hepatobiliary Disease, Tianjin 300170, China
c Tianjin Key Laboratory of Extracorporeal Life Support for Critical Diseases, Tianjin 300170, China
d Artificial Cell Engineering Technology Research Center, Tianjin 300170, China
∗ Corresponding author at: Department of Surgery, Third Central Hospital of Tianjin (Third Central Clinical College of Tianjin Medical University), Tianjin 300170, China.
E-mail address: wangyijun_carl@163.com (Y.-J. Wang).
# Contributed equally. |
|
|
|
|
Abstract In 2007, Schlitt firstly reported that the rapid compensatory increase of future liver remnant (FLR) after surgery can be achieved in a very short time which is known as a revolutionary breakthrough of liver surgery for huge or multiple liver cancer therapy [1]. de Santibañes and Clavien later proposed the medical term "ALPPS" [2]. Associating liver partition and portal vein ligation for staged hepatectomy (ALPPS) was mainly used for treating colorectal liver metastases (CRLM) and consequently was considered an emerging surgical technique for hepatocellular carcinoma (HCC). Up to now, surgical resection is still the most common curative treatment for liver cancer [3]. HCC is the major primary liver cancer in China, and 85%–90% patients with HCC present different degrees of cirrhosis [4], while only about 15%–30% of them are eligible for radical resection [5]. The main reason is that patients are not able to tolerate large-scale hepatectomy or one-stage radical hepatectomy due to the insufficient FLR after tumor resection. In recent years, ALPPS has emerged to win the surgical opportunity for patients with liver cancer who were initially considered unresectable. Also ALPPS prevents postoperative liver failure, especially for the patient who is not willing to receive a liver transplant.
|
|
|
|
|
|
|
|
|
2021, Vol. 20 
